Ovid Therapeutics Inc. (OVID) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2021
Loading P/E history...
OVID Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Ovid Therapeutics Inc. (OVID) trades at a price-to-earnings ratio of -11.4x, with a stock price of $2.73 and trailing twelve-month earnings per share of $-0.21.
The current P/E is 622% below its 5-year average of 2.2x. Over the past five years, OVID's P/E has ranged from a low of 1.8x to a high of 2.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, OVID trades at a 151% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, OVID trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our OVID DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
OVID P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | -Best | +68% | |
| $5B | 8.3Lowest | -Best | +264%Best | |
| $9B | 43.4 | -Best | +128% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
OVID Historical P/E Data (2021–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $3.21 | $1.75 | 1.8x | -16% |
| FY2021 Q3 | $3.36 | $1.79 | 1.9x | -14% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $3.91 | $1.68 | 2.3x | +7% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $4.02 | $1.50 | 2.7x | +23% |
Average P/E for displayed period: 2.2x
See OVID's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OVID Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OVID vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOVID — Frequently Asked Questions
Quick answers to the most common questions about buying OVID stock.
Is OVID stock overvalued or undervalued?
OVID trades at -11.4x P/E, below its 5-year average of 2.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does OVID's valuation compare to peers?
Ovid Therapeutics Inc. P/E of -11.4x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is OVID's PEG ratio?
OVID PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2021.